Cellectar Biosciences Inc. reported a net loss of $44.6 million, or $1.22 per share, for the fiscal year 2024. Despite the loss, the company has extended its cash runway to the fourth quarter of 2025, ...

DALLAS, March 31, 2025--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

If you want to know who really controls Arcus Biosciences, Inc. (NYSE:RCUS), then you'll have to look at the makeup of its share registry. With 51% stake, institutions possess the maximum shares ...

At this time, I would like to welcome everyone to the Pulse Biosciences’ Fourth Quarter 2024 Earnings Conference Call. All lines have been placed on mute to prevent any background noise.

Blue-chip tech stocks are a big part of President Donald Trump's portfolio, according to his latest financial disclosures.